Business Wire

NY-CLARITY-AI

29.10.2020 14:02:13 CET | Business Wire | Press release

Share
Clarity AI Raises $15m to Fuel Expansion of Platform That Empowers Investors to Manage the Societal Impact of Their Portfolios

Clarity AI announced today that it has closed a USD $15 million funding round led by Deutsche Börse AG and co-investor Mundi Ventures. Clarity AI empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders.

“Our purpose is simple: to measure the impact of companies on our society and planet,” said Rebeca Minguela, Founder and CEO of Clarity AI. “Investors attempting to evaluate impact have faced fragmented and unreliable data, inconsistent subjective definitions, and a lack of standards and tools for comprehensive analysis. Historically it has been too hard and resource-intensive to get accurate and transparent insights. Clarity AI provides a solution for that.”

Since its founding in 2017, Clarity AI has attracted a client network representing in excess of $3 trillion of assets and funding from investors, including Kibo Ventures, Founders Fund, Seaya Ventures and Matthew Freud. The company has built the most reliable tech platform on social and environmental impact, featuring more than 30,000 companies, 198 countries, 187 local governments and over 200,000 funds. The company uses proprietary technology and algorithms to produce transparent assessments for investors that are the most consistent and comprehensive available.

The “Sustainable Investment” market has grown 34% in the last two years and now represents one third of total global assets under management (AUM) – $30.7 trillion (of a total of $79.2 trillion).1 This rapid growth comes as research shows that 81% of investors want to better understand and improve the impact performance of their investments, with millennials (in particular) demanding greater social impact transparency in their portfolios.2

In the last six months, Clarity AI has seen a significant increase in demand for its services, including signing clients with eight times the assets under management as in the preceding period.

Minguela added: “2020 has seen extraordinary volatility and uncertainty – from COVID-19 to social justice protests. It has never been more important for investors to have accurate insights on the true impact of the companies in which they place their trust and their money. That is why we are scaling up our business to enable investors to identify and support those companies helping to solve society’s biggest challenges.”

The $15 million investment will drive Clarity AI’s sustainable expansion plans, including scaling-up investment in proprietary technology and AI, as well as integrating with the world’s largest financial services platforms. This approach will make it even quicker and easier for investors and corporations to analyze and report sustainability and impact.

Deutsche Börse AG led the funding round, underscoring the strong alignment of the Clarity AI product offering with Deutsche Börse’s expanding presence in the sustainability space and the importance of accelerating the growth of a European-focused Impact and ESG technology platform. Clarity AI and Deutsche Börse are also exploring potential collaboration opportunities in various Deutsche Börse business areas, including Qontigo, a leading provider of indices and analytics.

Sebastian Ceria, CEO of Qontigo, said: “This partnership reflects our mutual commitment to the ongoing enhancement of sustainable investing and the application of the latest technology in pursuit of this goal. We were very impressed by Rebeca and her team’s vision for Clarity AI and the advanced technology platform they have created. We are excited to be in a partnership that puts impact at the heart of investment.”

Clarity AI has received widespread recognition for its positive impact and innovative approach, including being selected as a 2020 Technology Pioneer by the World Economic Forum and receiving awards from the Harvard Innovation Lab and funding from Horizon 2020, the European Union’s Research and Innovation program.

Ends

NOTE TO EDITORS

ABOUT CLARITY AI

Clarity AI is a global fintech company that empowers investors to manage the impact of their portfolios through a proprietary technology platform that leverages big data and machine learning to assess sustainability for all societal stakeholders. Founded in 2017 by Rebeca Minguela, Clarity AI has offices in the US, UK and Spain and a client network with over $3T assets under management (AUM). The company has a team of over 100 technology, sustainability and research experts with collective experience from leading organizations, businesses and research institutions including NASA, the World Bank, Google, Netflix, McKinsey & Company, Morgan Stanley, J.P. Morgan, Harvard, M.I.T and more.

Rebeca Minguela is the Founder and CEO of Clarity AI. Previously, she led the Global Digital Transformation Program at Santander Bank after founding and leading Blink Booking, a last-minute hotel booking app acquired by Groupon in 2013, a company she moved to as Senior Director of Product and Technology thereafter. Rebeca has also worked at Bain Capital Private Equity, Boston Consulting Group, German Aerospace Agency, Siemens and IBM. She holds an MBA degree with distinction from Harvard Business School and has won several awards, including Top 25 Women Leaders in Financial Technology in 2019 and 2020, Young Global Leader by the World Economic Forum in 2017 and European Young Leader in 2018.

For more information, visit https://clarity.ai/

ABOUT DEUTSCHE BÖRSE

As an international exchange organisation and innovative market infrastructure provider, Deutsche Börse Group ensures markets characterised by integrity, transparency and stability. With its wide range of products, services and technologies, the Group organises safe and efficient markets for sustainable economies.

Its business areas extend along the entire value chain in exchange trading, including the admission, trading and clearing, and custody of securities and other financial instruments, the dissemination of market data, as well as the management of collateral and liquidity. As a technology company, the Group develops state-of-the-art IT solutions and offers IT systems all over the world.

With around 6,000 employees, the Group has its headquarters in the financial centre of Frankfurt/Rhine-Main, as well as a strong global presence in 38 locations such as Luxembourg, Prague, London, New York, Chicago, Hong Kong, Singapore, Beijing, Tokyo and Sydney.

ABOUT ALMA MUNDI VENTURES

Alma Mundi is a Venture Capital fund investing in B2B tech and Insurtech startups across Europe, the United States and Israel. The investments range from early Seed and Series A, to Series B and later stages. The headquarters are in Madrid and offices in Barcelona, London and Tel Aviv. The portfolio includes startups in London, Paris, Amsterdam, Berlin, Tel Aviv, San Francisco and New York. They bring value to entrepreneurs by leveraging their LPs, leading European insurers, and a global network, called the Mundi Club, which groups more than 750 C-level executives in more than 50 cities worldwide.

1 Gl obal Asset Management 2018: The Digital Metamorphosis, https://www.bcg.com/publications/2018/global-asset-management-2018-digital-metamorphosis ; Global Sustainable Investment Alliance: 2018 Global Sustainable Investment Review, http://www.gsi-alliance.org/wp-content/uploads/2019/03/GSIR_Review2018.3.28.pdf
2 Har vard Law School Forum on Corporate Governance: Institutional Investor Survey 2020, https://corpgov.law.harvard.edu/2020/03/25/institutional-investor-survey-2020/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye